US Bancorp
CMPX icon

US Bancorp’s Compass Therapeutics CMPX Stock Holding History

US Bancorp’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$407 Buy
+77
New +$444 ﹤0.01% 4021
2025
Q2 		– Sell
-65
Closed -$124 – 4186
2025
Q1 		$124 Buy
+65
New +$173 ﹤0.01% 4132

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

US Bancorp's CMPX Position: Q1 2026 in Review

US Bancorp opened a new position in Compass Therapeutics (CMPX) in Q1 2026: 77 shares worth $407. The stake represents ﹤0.01% of the portfolio and ranks #4021 among its holdings. This is a return to the name: US Bancorp previously reported a position in CMPX as recently as Q1 2025.

US Bancorp first reported a position in CMPX in Q1 2025 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • US Bancorp held 77 shares of Compass Therapeutics worth $407 as of Q1 2026.
  • Compass Therapeutics was a new US Bancorp position in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #4021 holding.
  • US Bancorp first reported a position in Compass Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.